Clinical Trials
41 trialsNCT06788509 2026-05-08
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT03441113 2026-04-20
Extended Access of Momelotinib in Adults With Myelofibrosis
GlaxoSmithKline
Phase 2 Active not recruiting
NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT05933070 2026-03-30
LAUREL
Inmune Bio, Inc.
Phase 1 Terminated
NCT04472598 2026-03-23
TRANSFORM-1
AbbVie
Phase 3 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT04468984 2026-01-09
TRANSFORM-2
AbbVie
Phase 3 Active not recruiting
NCT03573310 2025-12-18
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
Phase 1 Completed
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT02158858 2025-10-08
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT05482971 2025-08-13
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
PharmaEssentia
Phase 2 Active not recruiting
NCT04454658 2025-07-16
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Active not recruiting
NCT05282108 2025-03-26
CARCML
Hikma Pharmaceuticals LLC
Recruiting
NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT01943851 2024-10-01
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
GlaxoSmithKline
Phase 2 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT02520427 2024-07-31
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Amgen
Phase 1 Terminated
NCT04912063 2024-02-26
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
Phase 1 Terminated
NCT05444972 2023-12-11
METER
AbbVie
Completed
NCT02498665 2023-11-14
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03593915 2023-11-09
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT04480086 2023-08-29
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Terminated
NCT02440685 2023-06-07
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Phase 1/2 Terminated
NCT03614728 2023-02-06
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
GlaxoSmithKline
Phase 1/2 Terminated
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT02124772 2021-07-14
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis
Phase 1/2 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT03099031 2019-12-16
PREDICARE
LEO Pharma
Completed
NCT01201811 2019-12-05
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Celgene
Phase 4 Completed
NCT00607997 2017-06-28
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
Phase 2 Completed
NCT00246662 2017-03-30
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Sunesis Pharmaceuticals
Phase 1 Completed
NCT01751867 2016-04-05
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Completed
NCT01211691 2015-11-17
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Humanigen, Inc.
Phase 1/2 Suspended
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT01378416 2011-07-12
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Eisai Inc.
Phase 1 Completed
NCT00689000 2010-10-22
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
Chroma Therapeutics
Phase 1/2 Completed
NCT00230178 2010-01-12
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Sanofi
Phase 3 Completed